Morgan Stanley raised the firm’s price target on Omada Health (OMDA) to $32 from $30 and keeps an Overweight rating on the shares. Q3 revenue increased 49% year-over-year and beat by 11%, and the company crossed the threshold to EBITDA profitability, the analyst tells investors in a research note. The firm added that momentum continues, and the big development on the quarterly call was expanding its GLP-1 offering to include prescribing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health price target raised to $28 from $27 at Evercore ISI
- Omada Health, Inc.: Strong Revenue Momentum and Strategic Partnerships Drive Buy Rating
- Omada Health, Inc.: Strong Market Position and Growth Potential Drive Buy Rating
- Omada Health price target raised to $29 from $28 at Barclays
- Omada Health Reports Strong Q3 2025 Growth